An enzyme-responsive double-locked amonafide prodrug for the treatment of glioblastoma with minimal side effects.

Amonafide (ANF), a topoisomerase II inhibitor and DNA intercalator, has exhibited promise in phase II trials but faces significant limitations due to adverse side effects. Here, we have developed a novel enzyme-triggered fluorogenic prodrug, AcKLP, that incorporates dual-locked enzyme activation, ensuring that the prodrug remains inactive until it confronts the unique enzymatic environment of glioblastoma cells. This approach minimizes premature activation and reduces toxicity to normal cells, with an IC > 100 μM for human umbilical vein endothelial cells (HUVEC) and ∼2.

Sulindac selectively induces autophagic apoptosis of GABAergic neurons and alters motor behaviour in zebrafish.

Nonsteroidal anti-inflammatory drugs compose one of the most widely used classes of medications, but the risks for early development remain controversial, especially in the nervous system. Here, we utilized zebrafish larvae to assess the potentially toxic effects of nonsteroidal anti-inflammatory drugs and found that sulindac can selectively induce apoptosis of GABAergic neurons in the brains of zebrafish larvae brains. Zebrafish larvae exhibit hyperactive behaviour after sulindac exposure.

In situ interfacial architecture of lithium vanadate-based cathode for printable lithium batteries.

Most LiVO anodes are obtained by pre-architecture methods in which LiVO anode materials are prepared with more than six key processes including high-temperature annealing and long preparation time. Herein, we propose an post-architecture strategy including LiVO-precursor solution (ink) preparation and then annealing at 250°C. The integrated LiVO based electrode not only possesses good electrical conductivity and porous microstructure but also has superior stability because of Cu anchoring and inclusion by catalysis.

Anti-endometriosis Mechanism of Based on Network Pharmacology.

(JFS) is the new formula originated from classic formula, composed with ligustrazine, ferulic acid, and tetrahydropalmatine. Previously JFS inhibited the growth of endometriosis (EMS) with unclear mechanism, especially in metastasis, invasion, and epithelial-mesenchymal transition. In this study, network pharmacology was performed to explore potential mechanism of JFS on EMS.

Lidamycin decreases CD133 expression in hepatocellular carcinoma via the Notch signaling pathway.

Cluster of differentiation (CD)133 is considered a molecular marker of cancer stem cells in hepatocellular carcinoma. In the present study, the effect of lidamycin (LDM) on CD133 expression in hepatocellular carcinoma (Huh7 cells) was evaluated and the potential molecular mechanism was investigated. Flow cytometry analysis, as well as sorting, sphere formation and western-blot assays, were performed to explore the effects of LDM on CD133 expression.

Bimolecular-induced hierarchical nanoporous LiTi(PO)/C with superior high-rate and cycling performance.

We employed a facile bimolecular (glucose and DMEA) assisted hydrothermal reaction and a solid-state reaction to obtain carbon-coated hierarchical LiTi(PO) on a large scale. The nanoporous material exhibits excellent high-rate and cycling performance owing to enhanced electronic conductivity from the ultrathin carbon layer, Ti and the shortened path for Li diffusion by nanoporous frameworks.

[Study of solid-phase time-resolved fluorescence label immunoassay].

This paper describes optimal conditions for HBsAbIgG labeling with a new fluorescence probe, 4,7-bis-chorosulfophenyl-1,10-phenanthroline-2,9-dicarboxylic acid (BCPDA) for the solid phase time-resolved fluorimmunoassay (TRFIA). The result of experiment under states clearly that BCPDA may react with protein under relative mild condition. The relative bioactivity of reacted protein was more than 80%.

[Synthesis and characterization of a time-resolved fluorescence analysis chelate reagent-BCPDA].

In this paper, we report on a solid phase time-resolved fluorescence immunoassay chelate reagent-4,7-bis(chlorosulfophenyl)-1,10-phenanthroline-2,9-dicarboxylic acid (BCPDA), which is suitable as a fluorescent labeling agent. The five step synthesis product of BCPDA was presented for improving the purity of the product based on the three step synthesis product. The approach involves chlorization, hydrolyzing the ester, preparing disodium, carboxylate to diacid, sulfonation.